The prospect of simplified dengue prevention has moved closer to reality with evidence that immunity can persist for years after a single vaccination. For tropical and subtropical regions where dengue affects 390 million people annually, reducing the vaccination burden from multiple doses to one represents a significant public health advancement. The Butantan Institute's tetravalent vaccine demonstrated sustained protection against DENV-1 and DENV-2 serotypes over five years in Brazilian participants aged 2-59 years. This single-dose regimen maintained efficacy regardless of whether individuals had previous dengue exposure, addressing a critical challenge that has limited other dengue vaccines. The phase 3 trial tracked 16,235 participants through extended follow-up, revealing consistent safety profiles with no increased risk of severe dengue in seronegative individuals. However, protection against DENV-3 and DENV-4 serotypes remained limited, highlighting the ongoing complexity of developing comprehensive dengue immunity. This represents incremental but meaningful progress in dengue vaccine development, particularly given the checkered history of dengue vaccination programs. The Sanofi Dengvaxia vaccine faced significant setbacks when it increased disease severity in seronegative recipients, leading to restricted use recommendations. The Butantan vaccine's safety profile across serostatus groups suggests a more favorable risk-benefit calculation. While complete four-serotype protection remains elusive, the durability of single-dose immunity against two major circulating strains offers a pragmatic pathway forward for endemic regions. The simplified dosing schedule could dramatically improve vaccination coverage in resource-limited settings where multi-dose regimens face logistical challenges.